camrelizumab + pemetrexed + platinum

Camrelizumab + pemetrexed + platinum is a combination regimen used primarily as first-line therapy for advanced non-squamous non-small-cell lung cancer (NSCLC) without EGFR or ALK alterations. Camrelizumab is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses. Pemetrexed is an antifolate chemotherapy agent that inhibits multiple folate-dependent enzymes involved in nucleotide synthesis, leading to inhibition of tumor cell proliferation. The "platinum" component refers to a platinum-based chemotherapeutic agent—most commonly carboplatin or cisplatin—which forms DNA crosslinks and induces apoptosis in rapidly dividing cells. This combination has demonstrated significant improvements in progression-free survival and overall survival compared with chemotherapy alone, with manageable toxicity profiles. It has received regulatory approval as standard-of-care first-line therapy for advanced non-squamous NSCLC without targetable driver mutations[1][2][5].

Other names

camrelizumab plus pemetrexed and platinumcamrelizumab plus carboplatin and pemetrexedcamrelizumab plus cisplatin and pemetrexed